These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17604501)

  • 1. Ras as a therapeutic target in hematologic malignancies.
    Alvarado Y; Giles FJ
    Expert Opin Emerg Drugs; 2007 May; 12(2):271-84. PubMed ID: 17604501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
    Badar T; Cortes JE; Ravandi F; O'Brien S; Verstovsek S; Garcia-Manero G; Kantarjian H; Borthakur G
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):433-438.e2. PubMed ID: 25795639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
    Crul M; de Klerk GJ; Beijnen JH; Schellens JH
    Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors.
    Daley GQ
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):11-4. PubMed ID: 12783369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ras signaling pathway proteins as therapeutic targets.
    Adjei AA
    Curr Pharm Des; 2001 Nov; 7(16):1581-94. PubMed ID: 11562300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the RAS signaling pathway in malignant hematologic diseases.
    Morgan MA; Ganser A; Reuter CW
    Curr Drug Targets; 2007 Feb; 8(2):217-35. PubMed ID: 17305500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyl transferase inhibitors in myeloid malignancies.
    Lancet JE; Karp JE
    Blood Rev; 2003 Sep; 17(3):123-9. PubMed ID: 12818222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F
    Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.
    Lancet JE; Karp JE
    Blood; 2003 Dec; 102(12):3880-9. PubMed ID: 12920034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion.
    Clark SS; Zhong L; Filiault D; Perman S; Ren Z; Gould M; Yang X
    Clin Cancer Res; 2003 Oct; 9(12):4494-504. PubMed ID: 14555523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
    Rowinsky EK; Windle JJ; Von Hoff DD
    J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
    J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
    Karp JE; Lancet JE
    Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agents targeting ras signaling pathway.
    Dancey JE
    Curr Pharm Des; 2002; 8(25):2259-67. PubMed ID: 12369854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function.
    Clark GJ; Drugan JK; Terrell RS; Bradham C; Der CJ; Bell RM; Campbell S
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1577-81. PubMed ID: 8643674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking oncogenic Ras signaling for cancer therapy.
    Adjei AA
    J Natl Cancer Inst; 2001 Jul; 93(14):1062-74. PubMed ID: 11459867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.